Enfusion, Inc. Logo

Enfusion, Inc.

ENFN

(1.8)
Stock Price

9,79 USD

3.11% ROA

6.59% ROE

219.71x PER

Market Cap.

828.643.390,00 USD

27.99% DER

0% Yield

1.98% NPM

Enfusion, Inc. Stock Analysis

Enfusion, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Enfusion, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (27%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 ROE

ROE in an average range (14.64%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (9.26%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

6 PBV

The stock's high Price-to-Book Value (P/BV) ratio (18.33x) suggests it's overvalued, potentially making it an expensive investment.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-2.520) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Enfusion, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Enfusion, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Enfusion, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Enfusion, Inc. Revenue
Year Revenue Growth
2019 59.027.000
2020 79.565.000 25.81%
2021 111.700.000 28.77%
2022 150.349.000 25.71%
2023 177.428.000 15.26%
2023 174.535.000 -1.66%
2024 197.820.000 11.77%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Enfusion, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2019 4.146.000
2020 6.318.000 34.38%
2021 153.400.000 95.88%
2022 17.163.000 -793.78%
2023 19.748.000 13.09%
2023 19.893.000 0.73%
2024 24.384.000 18.42%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Enfusion, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 16.625.000
2020 35.888.000 53.68%
2021 150.614.000 76.17%
2022 68.764.000 -119.03%
2023 66.884.000 -2.81%
2023 64.635.000 -3.48%
2024 74.692.000 13.46%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Enfusion, Inc. EBITDA
Year EBITDA Growth
2019 15.023.000
2020 8.447.000 -77.85%
2021 -273.094.000 103.09%
2022 -5.620.000 -4759.32%
2023 21.156.000 126.56%
2023 20.535.000 -3.02%
2024 22.304.000 7.93%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Enfusion, Inc. Gross Profit
Year Gross Profit Growth
2019 42.066.000
2020 58.207.000 27.73%
2021 79.855.000 27.11%
2022 103.249.000 22.66%
2023 119.400.000 13.53%
2023 116.894.000 -2.14%
2024 133.972.000 12.75%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Enfusion, Inc. Net Profit
Year Net Profit Growth
2019 12.656.000
2020 4.061.000 -211.65%
2021 -282.242.000 101.44%
2022 -13.263.000 -2028.04%
2023 7.312.000 281.39%
2023 6.025.000 -21.36%
2024 7.304.000 17.51%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Enfusion, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 0 0%
2021 -4 100%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Enfusion, Inc. Free Cashflow
Year Free Cashflow Growth
2019 7.877.000
2020 -3.403.000 331.47%
2021 -8.332.000 59.16%
2022 6.225.000 233.85%
2023 14.812.000 57.97%
2023 9.499.000 -55.93%
2024 4.608.000 -106.14%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Enfusion, Inc. Operating Cashflow
Year Operating Cashflow Growth
2019 12.306.000
2020 1.665.000 -639.1%
2021 -318.000 623.58%
2022 14.156.000 102.25%
2023 24.483.000 42.18%
2023 12.106.000 -102.24%
2024 7.314.000 -65.52%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Enfusion, Inc. Capital Expenditure
Year Capital Expenditure Growth
2019 4.429.000
2020 5.068.000 12.61%
2021 8.014.000 36.76%
2022 7.931.000 -1.05%
2023 9.671.000 17.99%
2023 2.607.000 -270.96%
2024 2.706.000 3.66%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Enfusion, Inc. Equity
Year Equity Growth
2019 -117.879.000
2020 -233.559.000 49.53%
2021 97.441.000 339.69%
2022 103.444.000 5.8%
2023 73.277.000 -41.17%
2023 77.482.000 5.43%
2024 89.415.000 13.35%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Enfusion, Inc. Assets
Year Assets Growth
2019 23.197.000
2020 39.099.000 40.67%
2021 106.085.000 63.14%
2022 123.783.000 14.3%
2023 101.740.000 -21.67%
2023 108.972.000 6.64%
2024 120.090.000 9.26%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Enfusion, Inc. Liabilities
Year Liabilities Growth
2019 141.076.000
2020 272.658.000 48.26%
2021 8.644.000 -3054.3%
2022 20.339.000 57.5%
2023 28.463.000 28.54%
2023 31.490.000 9.61%
2024 30.675.000 -2.66%

Enfusion, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.04
Net Income per Share
0.04
Price to Earning Ratio
219.71x
Price To Sales Ratio
4.4x
POCF Ratio
31.12
PFCF Ratio
51.69
Price to Book Ratio
12.77
EV to Sales
4.31
EV Over EBITDA
48.71
EV to Operating CashFlow
30.78
EV to FreeCashFlow
50.66
Earnings Yield
0
FreeCashFlow Yield
0.02
Market Cap
0,83 Bil.
Enterprise Value
0,81 Bil.
Graham Number
0.8
Graham NetNet
0.31

Income Statement Metrics

Net Income per Share
0.04
Income Quality
5.75
ROE
0.07
Return On Assets
0.03
Return On Capital Employed
0.06
Net Income per EBT
0.51
EBT Per Ebit
1.13
Ebit per Revenue
0.03
Effective Tax Rate
0.27

Margins

Sales, General, & Administrative to Revenue
0.39
Research & Developement to Revenue
0.13
Stock Based Compensation to Revenue
0.09
Gross Profit Margin
0.67
Operating Profit Margin
0.03
Pretax Profit Margin
0.04
Net Profit Margin
0.02

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.29
Free CashFlow per Share
0.17
Capex to Operating CashFlow
0.39
Capex to Revenue
0.05
Capex to Depreciation
1.02
Return on Invested Capital
0.06
Return on Tangible Assets
0.03
Days Sales Outstanding
65.25
Days Payables Outstanding
4.78
Days of Inventory on Hand
0
Receivables Turnover
5.59
Payables Turnover
76.31
Inventory Turnover
0
Capex per Share
0.11

Balance Sheet

Cash per Share
0,37
Book Value per Share
0,97
Tangible Book Value per Share
0.97
Shareholders Equity per Share
0.7
Interest Debt per Share
0.2
Debt to Equity
0.28
Debt to Assets
0.15
Net Debt to EBITDA
-0.99
Current Ratio
4.15
Tangible Asset Value
0,09 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
92021000
Working Capital
0,06 Bil.
Intangibles to Total Assets
0
Average Receivables
0,03 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Enfusion, Inc. Dividends
Year Dividends Growth

Enfusion, Inc. Profile

About Enfusion, Inc.

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.

CEO
Mr. Oleg Movchan
Employee
1.102
Address
125 South Clark Street
Chicago, 60603

Enfusion, Inc. Executives & BODs

Enfusion, Inc. Executives & BODs
# Name Age
1 Mr. Joseph Defeo
Global Head of Managed Services Production
70
2 Mr. Neal Pawar
Chief Operating Officer
70
3 Ms. Valeria Gutowski
Chief Accounting Officer
70
4 Mr. Daniel Groman
Chief Technology Officer
70
5 Mr. Ignatius Tochukwu Njoku
Head of Investor Relations
70
6 Mr. Matthew R. Campobasso
General Counsel & Corporate Secretary
70
7 Ms. Bronwen Bastone
Chief People Officer
70
8 Mr. Oleg Movchan
Chief Executive Officer & Director
70
9 Mr. Bradley Herring
Chief Financial Officer
70
10 Mr. Stephen Malherbe
Managing Partner
70

Enfusion, Inc. Competitors